http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Amgen Announces 2020 Third Quarter Dividend
-
Amgen Appoints Amy E. Miles To Board Of Directors
-
The US, Australia and Canada lead, but no G20 country is fully prepared for the needs of ageing populations, according to new research from the Economist Intelligence Unit
-
Amgen Foundation Awards Khan Academy An Additional $3 Million To Support Science Learning And Educational Equity Amid COVID-19
-
Amgen Announces Additional Investment In BeiGene
-
Amgen (AMGN) Confirms Appeals Court Affirms Validity Of Enbrel Patents Injunction Against Sandoz's Infringement Stands
-
Appeals Court Affirms Validity Of Enbrel® (etanercept) Patents Injunction Against Sandoz's Infringement Stands
-
Amgen (AMGN) Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries
-
Amgen Is Supporting Advancement Of AMG 634 For Global Health Diseases In Developing Countries
-
Launch of EIU report showing lack of integrated follow up care can increase risk of subsequent heart attack or stroke in APAC economies
-
Amgen To Present At The BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
-
Amgen To Present At The Goldman Sachs 41st Annual Global Healthcare Conference
-
Amgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program
-
Amgen To Present At The Jefferies 2020 Virtual Healthcare Conference
-
Pre-Open Stock Movers 05/28: (PHAS) (TGI) (DLTR) (TOL) (ALXN) (HTZ) (TWTR) (More...)
-
Amgen To Webcast Investor Meeting At 56th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
-
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
-
Amgen Showcases Oncology Pipeline At ASCO 2020
-
Amgen To Present At The Bank Of America Merrill Lynch Virtual Global Healthcare Conference
-
Amgen (AMGN) and Cytokinetics (CYTK) Announce FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
-
FDA Grants Fast Track Designation for Omecamtiv Mecarbil in Heart Failure
-
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
-
Amgen (AMGN) Announces Positive Top-Line Results From Otezla Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis
-
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis
-
Amgen (AMGN) Announces KYPROLIS Patents Upheld Against Generic Manufacturer
-
KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer
-
Amgen To Present At The SunTrust Robinson Humphrey Life Sciences Summit Virtual Meeting Series
-
Amgen Reports First Quarter 2020 Financial Results
-
Amgen Announces Webcast Of 2020 First Quarter Financial Results
-
Amgen And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strategic Collaboration
-
Amgen (AMGN), Adaptive Biotechnologies (ADPT) Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
-
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
-
Amgen Establishes Wholly-Owned Affiliate In Japan
-
Amgen (AMGN) Reports Positive Results At ACC20/WCC from Phase 3B Study Of Repatha (Evolocumab)
-
Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol
-
Amgen And The Amgen Foundation Commit Up To $12.5 Million To Support COVID-19 Relief Efforts
-
Amgen Announces 2020 Second Quarter Dividend
-
Amgen To Present At The Cowen 40th Annual Healthcare Conference
-
Amgen (AMGN) Cytokinetics (CYTK) and Servier Report Continuation of GALACTIC-HF Following Planned Interim Analysis
-
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
-
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
-
Cytokinetics (CYTK) Reports Publication of Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure
-
Amgen Reports Fourth Quarter And Full Year 2019 Financial Results
-
Amgen Announces Webcast Of 2019 Fourth Quarter And Full Year Financial Results
-
Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences
-
Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer
-
Amgen To Present At The 38th Annual J.P. Morgan Healthcare Conference
-
Amgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference
-
Amgen (AMGN) Commences Strategic Collaboration With BeiGene (BGNE) to Expand Oncology Presence in China
-
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

